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ABSTRACT
Hemolytic uremic syndrome (HUS) is an uncommon but potentially life-threatening complication of hema-
topoietic stem cell transplantation. We retrospectively studied the medical records of 293 children who
underwent allogeneic bone marrow transplantation at St. Jude Children’s Research Hospital between 1992 and
1999 to describe the clinical course of and to identify risk factors for transplant-associated HUS. Conditioning
regimens included cyclophosphamide, cytarabine, and total body irradiation for patients with hematologic
malignancies (n  244); patients with nonmalignant diseases (n  49) received disease-specific regimens.
Grafts from unrelated or mismatched related donors were depleted of T lymphocytes, whereas matched sibling
grafts were unmanipulated. All patients received cyclosporine as prophylaxis for graft-versus-host disease.
Recipients of grafts from matched siblings also received pentoxifylline or short-course methotrexate. HUS
developed in 28 (9.6%) patients at a median of 171 days after transplantation. We identified older donor age
(P  .029), use of antithymocyte globulin in the conditioning regimen (P  .008), and recipient CMV
seronegativity (P .011) as being associated with an increased risk of HUS. With a multiple regression analysis,
the use of antithymocyte globulin (  .86; P  .04) and recipient cytomegalovirus seronegativity (  .93;
P  .035) remained significant risk factors for the development of HUS.
© 2005 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Thrombotic microangiopathy is a well-described,
otentially lethal complication seen in patients under-
oing hematopoietic stem cell transplantation [1-3].
ts severity ranges from mild disease characterized by
emolytic anemia, thrombocytopenia, and renal insuf-
ciency to a more severe disorder with neurologic
bnormalities and renal failure, sometimes resulting in
eath. Thrombotic microangiopathy is described in 2
orms: an acute, fulminant form with prominent cen- [
12ral nervous system (CNS) symptoms, which is often
eferred to as thrombotic thrombocytopenic purpura
TTP), and another form characterized by chronic
enal insufﬁciency, which is often referred to as he-
olytic uremic syndrome (HUS). This article focuses
n the latter. The conditioning regimen, posttrans-
lantation immunosuppressive agents, viral infections,
adiation, and graft-versus-host disease (GVHD) have
een proposed as potential causes or contributory
gents, but the precise etiology remains unknown
3-7]. In this article, we describe the risk factors for
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Transplant-Associated HUS
Bnd the clinical course of HUS in children who have
ndergone allogeneic bone marrow transplantation
BMT).
ATIENTS AND METHODS
atients
We reviewed the records of 293 consecutive children
ho underwent allogeneic BMT after a myeloablative
onditioning regimen between 1992 and 1999 at St.
ude Children’s Research Hospital and identiﬁed 29
atients who developed HUS. One patient who de-
eloped HUS after a second allogeneic transplantation
as excluded from the statistical analysis of cumulative
ncidence or risk factors. Patients were treated on
nstitutional protocols approved by the institutional
eview board, and written informed consent was ob-
ained from the patients, their parents, or their legal
uardians. Patient details are shown in Table 1.
For this study, HUS was deﬁned as the triad of
enal insufﬁciency, hemolytic anemia, and thrombo-
ytopenia. For patients with HUS, the peripheral
lood smear showed evidence of intravascular hemo-
ysis (schistocytes observed); a direct antiglobulin test
as negative, with no evidence of immunologically
ediated thrombocytopenia or disseminated intravas-
ular coagulation; and the lactate dehydrogenase level
as increased. Hypertension was deﬁned as systolic or
iastolic blood pressure (or both) greater than or equal
o that on the 90th percentile for age and sex. Renal
unction was assessed by measurement of plasma cre-
tinine levels and by urinalysis. Diethylenetriamine-
able 1. Descriptive Statistics Analysis Results
Variable Group n
ge at BMT (y) Total 293
HUS/TTP 28
Control 265
onor age (y) Total 292
HUS/TTP 28
Control 264
-cell dose (CD3/kg) Total 181
HUS/TTP 22
Control 159
otal cell dose (TNC/kg) Total 292
HUS/TTP 28
Control 264
D34 cells (CD34/kg) Total 179
HUS/TTP 21
Control 158
yclophosphamide dose (mg/kg) Total 293
HUS/TTP 28
Control 265
ollow-up (years after BMT) Total 293
HUS/TTP 28
Control 265
onor age and cyclophosphamide dose differed signiﬁcantly betwee
results were based on the Student t test.
B&MTentaacetic acid (DTPA) clearances were obtained in
atients with abnormal renal function.
onditioning Regimen
All patients with hematologic malignancies and
istiocytic disorders received cytarabine (3 g/m2 per
ose; 6 doses) and cyclophosphamide (45 mg/kg per
ose; 2 doses), and mesna (45 mg/kg divided into 5
oses) was administered before and 3, 6, 9, and 12
ours after each dose of cyclophosphamide [8]. These
atients also received total body irradiation (TBI) in 8
ractions, for a total of 12 Gy (matched sibling marrow
ecipients) or 14 Gy (unrelated or mismatched family
ember marrow recipients). Patients with severe aplas-
ic anemia received cyclophosphamide-based regimens.
ther patients with nonmalignant disorders received
usulfan (1 mg/kg per dose; 16 doses) and cyclophos-
hamide (50 mg/kg per dose; 4 doses), and mesna
roprotection was given for patients with hematologic
alignancies. Patients with osteogenesis imperfecta
eceived busulfan-based regimens as previously de-
cribed [9]. Equine antithymocyte globulin (ATG)
as administered as part of the conditioning regimen
o patients who received marrow from unrelated or
ismatched family donors (121 patients with hema-
ologic malignancies and 35 patients with nonmalig-
ant diseases).
rophylaxis for GVHD
Marrow from mismatched family members and
rom unrelated donors was depleted ex vivo of approx-
Range Median P Value
0.08–24.1 9.7
0.08–21.3 8.2 .69
0.10–24.1 10.0
0.6–53 26
10.0–42 31.0 .011
0.6–53 25.5
1.7  104–1.64  107 1.0  106
4.61  104–2.77  106 9.875  105 .37
1.7  104–1.64  107 1.0  106
1.9  107–4.69  109 1.655  108
2.31  107–5.42  108 1.185  108 .079
1.9  107–4.69  109 1.715  108
1.52  104–9.4  107 2.43  106
7.09  105–7.83  106 2.5  106 .25
1.52  104–9.4  107 2.4  106
26–990 90
76–138 89 .011
26–990 90
0.0356–8.4846 1.9712
0.6270–8.31211 2.4832
0.0356–8.4846 1.2293
US group and the control group. The P values were both .011. Then the H913
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9mately 1.5 log T lymphocytes by use of monoclonal
ntibodies to CD6 and CD8 plus rabbit complement
8]. Beginning 2 days before transplantation, all recip-
ents received cyclosporine at dosages adjusted to yield
hole-blood levels of 200 to 350 ng/mL. Patients given
atched sibling marrow received additional GVHD
rophylaxis with pentoxifylline or short-course metho-
rexate.
lassification of Adverse Events
Acute and chronic GVHD were graded according
o standard criteria [10]. Patients with mild or mod-
rate GVHD (grade I or II) were treated with meth-
lprednisolone (1-2 mg/kg daily). If GVHD remained
t grade II for more than 7 days or progressed, the
teroid dosage was increased to 5 to 10 mg/kg daily, or
econd-line therapy with ATG or ABX-CBL was ini-
iated [11]. Regimen-related toxicity was scored by
sing National Cancer Institute Common Toxicity
riteria.
upportive Care
Prophylaxis for Pneumocystis carinii pneumonia con-
isted of treatment with trimethoprim-sulfamethoxazole
co-trimoxazole) 5 mg/kg daily divided into 2 doses, 3
imes a week, for all patients with an absolute neutrophil
ount 1.0  109/L. Allograft recipients who were se-
opositive for cytomegalovirus (CMV) or had a CMV-
eropositive donor and whose absolute neutrophil
ount exceeded 0.5  109/L for 2 days were given
anciclovir (5 mg/kg twice daily for 14 days and then
mg/kg daily 5 days per week) until day 120 after
ransplantation. Intravenous immunoglobulin (500
g/kg) was given weekly until day 120. Recipients of
cell–depleted grafts continued to receive intrave-
ous immunoglobulin until 12 months after alloge-
eic transplantation. Patients given T cell–depleted
rafts were eligible to receive donor-derived cytotoxic
cells speciﬁc for Epstein-Barr virus as prophylaxis
gainst Epstein-Barr virus–associated lymphoprolif-
rative disease [12]. No preventive treatment for fun-
al infection or veno-occlusive disease was routinely
rovided.
tatistical Methods
Only recipients of ﬁrst allogeneic transplants were
ncluded in the statistical analysis. Because no cases of
US occurred in patients with nonmalignant diseases
fter a ﬁrst allogeneic transplantation, risk factors
ere assessed only in patients with malignant diseases.
he Student test was used to assess the differences in
istribution of the continuous variables between the
US and control groups. The cumulative incidence
f HUS was estimated with Prentice and colleagues’
ethod [13]. The effects of several categorical vari-
bles were evaluated 1 at a time with Gray’s method *
1414]. However, for continuous variables, we used the
roportional hazard model for competing risks pro-
osed by Fine and Gray [15]. An analysis to identify
isk factors for HUS was performed in the malignant
isease group only. These risk factors included diagno-
is, donor type, use of an ATG-containing conditioning
egimen, donor CMV serology, recipient CMV serol-
able 2. Univariate Analysis Results*
Variable
2-y Cumulative
Incidence of HUS,
% (Mean  SE) P Value
iagnosis
ALL/NHL (n  67) 9.0  3.5 .67
AML/MDS (n  139) 12.9  2.9
CML (n  38) 10.5  5.1
onor
MMFM (n  33) 6.1  4.3 .11
Matched sibling (n  83) 7.2  2.9
Unrelated (n  128) 15.6  3.2
TG
Yes (n  117) 17.1  3.5 .0080
No (n  127) 6.3  2.2
CD
Yes (n  157) 14.0  2.8 .098
No (n  87) 6.9  2.7
onor CMV
Positive (n  106) 9.4  2.9 .41
Negative (n  138) 13.0  2.9
ecipient CMV
Positive (n  116) 6.0  2.2 .011
Negative (n  128) 16.4  3.3
onor-recipient sex match
Male/male (n  65) 18.5  4.9 .11
Female/female (n  72) 12.5  3.9
Male/female (n  42) 4.8  3.4
Female/male (n  65) 7.7  3.4
rior autologous transplantation
Yes (n  22) 22.7  9.4 .096
No (n  222) 10.4  2.0
isease status at BMT
CP1/CR1 (n  88) 14.8  3.8 .25
CP2/CR2 or more (n  51) 13.7  4.9
Others (n  105) 7.6  2.6
cute GVHD
Grade 0 or I (n  186) 12.9  2.5 .22
Grade II, III, or IV (n  58) 6.9  3.4
hronic GVHD
Yes (n  43) 16.3  5.7 .31
No (n  201) 10.4  2.2
MV reactivation
Yes (n  9) 0 .28
No (n  235) 11.9  2.1
rade 3-4 organ toxicity
Yes (n  22) 13.6  7.7 .70
No (n  222) 11.3  2.1
LL indicates acute lymphoblastic leukemia; HUS, hemolytic ure-
mic syndrome; NHL, non-Hodgkin lymphoma; AML, acute
myeloid leukemia; MDS, myelodysplastic syndrome; CML,
chronic myeloid leukemia; TCD, T-cell depletion; MMFM,
mismatched family member; GVHD, graft-versus-host-disease;
CP, chronic phase; CR, complete remission; ATG, antithymocyte
globulin; CMV, cytomegalovirus; BMT, bone marrow transplan-
tation; GVHD, graft-versus-host disease.For patients with malignant diseases only.
o
s
p
C
s
n
a
a
t
l
t
H
w
s
i
s
t
S
H
s
R
T
l
d
t
a
T
D
O
T
A
B
D
R
P
D
D
A
C
A
Transplant-Associated HUS
Bgy, donor-recipient CMV serology, donor-recipient
ex match, prior autologous transplantation, cyclophos-
hamide dose, presence of acute or chronic GVHD,
MV reactivation, disease status at BMT, and organ-
peciﬁc grade 3 or 4 toxicities (CNS, hepatic, pulmo-
ary, renal, and cardiac; Table 2). Multiple regression
nalysis using the proportional hazards model with
competing risk was used to analyze factors iden-
iﬁed as signiﬁcant in the univariate analysis. The
ength of time at risk for HUS was computed from
he date of BMT to the date of the diagnosis of
US, the date of death, or the date of last contact,
hichever came ﬁrst. Death from any cause was con-
idered a competing event. The criterion for signif-
cance for all analyses was a probability of .05. All
able 3. Patient Characteristics
Feature Category
HUS/TTP
(n  28)
iagnosis
ALL/NHL 6 (21.4%
AML/MDS 18 (64.3%
CML 4 (14.3%
Nonmalignant 0
utcome
Dead 6 (21.4%
Alive 22 (78.6%
CD
Yes 22 (78.6%
No 6 (21.4%
TG
Yes 20 (71.4%
No 8 (28.6%
usulfan
Yes 0
No 28 (100%
onor CMV
Negative 18 (64.3%
Positive 10 (35.7%
ecipient CMV
Negative 21 (75.0%
Positive 7 (25.0%
rior autologous transplantation
Yes 5 (17.9%
No 23 (82.1%
onor
MMFM 2 (7.1%)
Matched sibling 6 (21.4%
Unrelated 20 (71.4%
onor-recipient sex match
Male/male 12 (42.9%
Female/female 9 (32.1%
Male/female 2 (7.1%)
Female/male 5 (17.9%
cute GVHD
Grade II, III, or IV 4 (14.3%
Grade 0 or I 24 (85.7%
hronic GVHD
Yes 7 (25.0%
No 21 (75.0%
LL indicates acute lymphoblastic leukemia; NHL, non-Hodgk
syndrome; CML, chronic myeloid leukemia; TCD, T-cell dep
disease; ATG, antithymocyte globulin; CMV, cytomegalovirus;
purpura.
B&MTtatistical analyses used SAS release 8.1 (SAS Insti-
ute, Cary, NC) and Splus 2000 (Insightful Corp.,
eattle, WA). Factors associated with resolution of
US were assessed by using stepwise logistic regres-
ion.
ESULTS
ransplant Patient Characteristics
Two hundred forty-four patients with hemato-
ogic malignancies and 49 patients with nonmalignant
isorders underwent allogeneic BMT at our institu-
ion between 1992 and 1999 (Table 3). The median
ge at transplantation was 9.7 years (range, 0.08-24.1
Control
(n  265)
Total
(n  293)
61 (23.0%) 67 (22.9%)
121 (45.7%) 139 (47.4%)
34 (12.8%) 38 (13.0%)
49 (18.5%) 49 (16.7%)
140 (52.8%) 146 (49.8%)
125 (47.2%) 147 (50.2%)
159 (60.0%) 181 (61.8%)
106 (40.0%) 112 (38.2%)
131 (49.4%) 151 (51.5%)
134 (50.6%) 142 (48.5%)
28 (10.7%) 28 (9.6%)
237 (89.4%) 265 (90.4%)
148 (55.9%) 166 (56.7%)
117 (44.1%) 127 (43.3%)
138 (52.5%) 159 (54.6%)
125 (47.5%) 132 (45.4%)
17 (6.4%) 22 (7.5%)
248 (93.6%) 271 (92.5%)
42 (15.8%) 44 (15.0%)
99 (37.4%) 105 (35.8%)
124 (46.8%) 144 (49.2%)
68 (25.7%) 80 (27.3%)
75 (28.3%) 84 (28.7%)
49 (18.5%) 51 (17.4%)
73 (27.5%) 78 (26.6%)
58 (21.9%) 62 (21.2%)
207 (78.1%) 231 (78.8%)
41 (15.5%) 48 (16.4%)
224 (84.5%) 245 (83.6%)
phoma; AML, acute myeloid leukemia; MDS, myelodysplastic
MMFM, mismatched family member; GVHD, graft-versus-host
hemolytic uremic syndrome; TTP, thrombotic thrombocytopenic)
)
)
)
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9ears); 54% were male. Most patients underwent
MT to treat hematologic malignancies: 67 (23%)
ith acute lymphoblastic leukemia or non-Hodgkin
ymphoma, 139 (47%) with acute myeloid leukemia
AML)/myelodysplastic syndrome, and 38 (13%) with
hronic myeloid leukemia. Nonmalignant diagnoses
ncluded immunodeﬁciencies (n  16), severe aplastic
nemia (n  11), metabolic orders (n  4), histiocytic
isorders (n  4), hemoglobinopathies (n  4), and
one disorders (n  10). One hundred ﬁve (36%)
atients received grafts from matched sibling donors;
4 (15%), from mismatched family member donors;
nd 144 (49%), from unrelated donors matched at 5
n  54) or 6 (n  90) HLA loci. All patients received
yclophosphamide, 28 patients received busulfan, and
58 (88%) patients received TBI as part of the con-
itioning regimen. Twenty-two (7.5%) had received a
rior autologous BMT. Sixty-two (21%) patients de-
eloped grade II to IV acute GVHD; 48 (16.4%)
eveloped chronic GVHD. The median follow-up
as 1.97 years (range, 0.04-8.5 years).
US Patient Characteristics
HUS developed in 28 patients; the cumulative
ncidence of HUS was 9.6%. The median age at trans-
lantation was 8.2 years (range, 0.08-21.3 years); 17
61%) patients were male. The median time from
ransplantation to the onset of HUS was 171 days
range, 68-483 days). Compared with controls, pa-
ients who developed HUS had received grafts from
onors who were older (median, 31.0 years; range,
0.0-42.0 years; P  .011) than those who provided
rafts for patients who did not have HUS (median,
5.5 years; range, 0.6-53.0 years). Patients who had
US had undergone BMT to treat AML/myelodys-
lastic syndrome (n  16), chronic myeloid leukemia
n  4), secondary AML (n  1), acute lymphoblastic
eukemia (n  6), and severe aplastic anemia (n  1).
f the patients who had HUS, 6 received grafts from
atched sibling donors; 2 received grafts from mis-
atched family member donors, and the remaining 20
eceived grafts from matched unrelated donors. Sev-
nteen were no longer receiving transfusions at the
nset of HUS. Hemorrhagic cystitis was also diag-
osed in 6 patients, and the onset of hemorrhagic
ystitis was temporally related to the onset of HUS in
of these patients.
The cumulative incidence of HUS was 9.6% 
.7% in all patients and 11.5%  2.0% for patients
ith malignant disorders. The median follow-up time
or patients who developed HUS was 2.48 years
range, 0.6-8.3 years). No patient with a nonmalignant
isease developed HUS after the ﬁrst transplantation.
ne patient with Langerhans cell histiocytosis devel-
ped HUS after undergoing a second transplantation
or disease recurrence. c
16raft-versus-Host Disease
Five children were still receiving immunosuppres-
ion at the onset of HUS. Only 4 children were diag-
osed with grade II to IV acute GVHD. Grade I, II,
nd III were seen in 16 children, 3 children, and 1
hild, respectively. The onset of HUS followed the
iagnosis of acute GVHD within a mean of 4.9
onths (range, 1.9-15.8 months) in 17 patients and
ithin 1 month in 2 patients; 1 patient had HUS
efore acute GVHD developed. Five patients were
eceiving immunosuppressive treatment at the time of
nset of HUS.
linical Course
Six patients died. No death was directly related to
US. Two patients died of sepsis, 3 patients died of
ecurrent disease, and 1 died of GVHD. Four of the
atients who died had required dialysis: 1 patient re-
eived 2 dialysis treatments followed by partial recov-
ry of renal function before death of recurrent disease,
child had severe acute GVHD, 1 required hemodi-
lysis until the time of his death from aspergillosis,
nd 1 died of sepsis during maintenance hemodialysis.
one of the survivors required dialysis, but 2 patients
ith a chronic, worsening course were being coun-
eled regarding renal-replacement therapies when
heir renal function began to improve. One of these
hildren subsequently died of recurrent disease, and
he other continues to have moderately severe chronic
enal insufﬁciency with follow-up of 5 years.
rythropoietin
Erythropoietin (EPO) levels were measured in 21
atients during the acute phase of HUS, and nearly all
ad low values for their hemoglobin (median, 15.0
/L; range, 2.6-175.0 U/L; Figure 1). Intravenous
PO therapy was initiated in 23 patients; 6 patients
id not receive EPO at the discretion of the treating
igure 1. Relationship between erythropoietin levels and hemato-
rit in patients with HUS.
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Transplant-Associated HUS
Bhysician. EPO therapy was begun within 2 weeks of
iagnosis for 11 patients, before diagnosis (2 and 7
onths) of HUS for 2 patients, and at a mean of 5.8
eeks (range, 2-18 weeks) after diagnosis in 10 pa-
ients. The dosage was 350 U/kg/wk intravenously or
ubcutaneously divided into 3 doses per week. The
ose of EPO was reduced when red blood cell trans-
usion was no longer necessary and the hemoglobin
evel was stable or increasing. EPO therapy was dis-
ontinued after a mean of 6.5 months of treatment in
5 patients.
ypertension
Antihypertensive medications were required for
1 patients. The duration of treatment was 6
onths for 6 patients and was 6 months, but now
iscontinued, in 7. Eight patients continue to receive
ntihypertensive medications. A variety of agents were
rescribed, and many children required multiple
rugs during the acute and most active phase of renal
ailure. Calcium channel blockers were prescribed for
8 patients. Other vasodilators used primarily for
hort-term control of severe hypotension were hydral-
zine (n  4), minoxidil (n  2), prazosin (n  2), and
erazosin (n  1). Angiotensin-converting enzyme in-
ibitors, given to 8 patients, were used cautiously
ecause hyperkalemia and worsening renal function in
ome patients were relative contraindications. Beta
lockers were used to treat 7 patients, diuretics were
sed to treat 4 patients, and clonidine was used to treat
patient. Because of the retrospective, uncontrolled
ature of this study, we were not able to compare the
fﬁcacy of different antihypertensive agents for pa-
ients with HUS-related nephropathy.
enal Function
Glomerular ﬁltration rate (GFR) was calculated by
sing the Schwartz formula:
FR mL ⁄min ⁄ 1.73 m2
 height f ⁄ serum creatinine,
here the patient’s height was measured in centimeters
nd the serum creatinine concentration was measured in
illigrams per deciliter. A correction factor (f) of 0.55
as used for all patients except for 3 adolescent boys, for
hom f was 0.7. Fifteen patients were followed up for 24
onths after the onset of HUS. In this group of patients,
he mean calculated GFR declined at the onset of HUS
nd then increased at 12 and 24 months. DTPA clear-
nces were available before and after the onset of HUS
n 6 patients. Mean DTPA creatinine clearances before
nd after the onset of nephropathy were 124  35
L/min/1.73 m2 and 43 28 mL/min/1.73 m2, respec-
ively. The mean calculated GFRs for the same 6 chil-
ren were 123  32 mL/min/1.73 m2 and 91.5  55
L/min/1.73 m2, respectively. d
B&MTThis discrepancy in GFR values highlights the
otential inaccuracy of GFR clearances for children
ith renal injury: excretion of creatinine can occur via
he renal tubules after renal injury, and this leads to
verestimation of the creatinine clearance. For exam-
le, in 1 case, the calculated creatinine clearance was
80 mL/min/1.73 m2, and the serum creatinine level
as 0.3 mg/dL, whereas the DTPA clearance was only
2 mL/min/1.73 m2.
ther Evaluations
Complement 3 and complement 4 levels were
easured in 11 patients, and total serum hemolytic
omplement activity was measured in 9 patients. All
alues were within the reference range of the labora-
ory.
enal Biopsy Findings
Because patients with HUS are thrombocytope-
ic, patients did not routinely undergo renal biopsy at
ur institution. Two patients underwent renal biopsy
o conﬁrm HUS because of some atypical clinical
ndings. The ﬁrst child developed HUS 8 months
fter BMT associated with proteinuria and hyperten-
ion. A renal biopsy was performed to determine the
ause of proteinuria. The biopsy revealed HUS. The
econd child underwent renal biopsy during the acute
hase of HUS when he had malignant hypertension
nd severe renal insufﬁciency. His renal biopsy sample
howed ﬁndings consistent with acute HUS, as well as
bsolescent glomeruli (10%) and segmental sclerosis
n other glomeruli. Tubular cell atypia was also noted
hat was suggestive, but not diagnostic, of concomi-
ant viral infection. However, no viruses were detected
n renal biopsy by immunoﬂuorescence assays.
isk Factor Analysis
By using univariate analysis, the following factors
ere identiﬁed as being associated with an increased
isk of HUS: older donor age (P  .029), use of ATG
P  .008) in the conditioning regimen, and recipient
MV seronegativity (P  .011). Only the use of ATG
  .86; P  .041) and recipient CMV seronegativity
  .93; P  .035) remained signiﬁcant factors on
ultivariate analysis. An analysis of the same factors
evealed that none was predictive of recovery from
US.
ISCUSSION
In this retrospective study, we found by univariate
nalysis that children undergoing allogeneic BMT
ho received grafts from older donors, received ATG,
r were CMV seronegative were at increased risk for
eveloping HUS. Multiple regression analysis found
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9hat ATG recipients and CMV-seronegative recipi-
nts were at a higher risk for HUS.
The 2-year cumulative incidence of HUS in our
tudy was 9.6%  1.7%, which is within the wide
ange of incidences (1% to 20%) of thrombotic
icroangiopathy reported in the transplant literature
1-7]. In our series, HUS was a relatively late compli-
ation that began a median of 171 days after trans-
lantation, when most patients were no longer receiv-
ng immunosuppressive treatment. Other series have
eported an onset at approximately 2 months or
onger after transplantation [1-7].
Other investigators have attempted to identify fac-
ors associated with thrombotic microangiopathy (HUS
r TTP) in patients undergoing autologous or alloge-
eic hematopoietic stem cell transplantation [1-7].
hese factors include the use of grafts from unrelated
r mismatched family member donors, the presence of
rade III or IV acute GVHD, serious infections, and
he patient’s being older or female. However, in other
eries, younger patients were found to be at increased
isk for HUS [16]. Investigators have hypothesized
hat rapid endothelial replication in young people may
ncrease susceptibility to renal damage [17,18].
HUS and TTP not associated with BMT are
aused by a severe deﬁciency of the von Willebrand
actor–clearing protease ADAMTS13 [19]. Recent
tudies have identiﬁed antibodies against a protease
hat cleaves von Willebrand factor in the sera of pa-
ients with HUS/TTP [20]. Some studies have re-
orted an association of GVHD with the development
f HUS, thus allowing some to hypothesize that host-
eactive antibodies may be produced. Our study did
ot ﬁnd acute or chronic GVHD to be associated with
US. Other studies that have shown GVHD to be
ssociated with the development of HUS or TTP
ere in patients who received non–T cell–depleted
rafts. In fact, no studies have documented severe
eﬁciency of ADAMTS13 in the sera of patients with
ransplant-related HUS, and the etiology of this dis-
rder remains unknown [21].
Some studies have suggested that HUS may be
ue to toxicities from the conditioning regimen, such
hat it may be the result of chemotherapy- or radia-
ion-induced damage to the endothelial cells, similar
o veno-occlusive disease [22]. Our study did not ﬁnd
hat heavily pretreated patients had a higher risk of
his complication. For example, those who received
BI and those who had received a prior autologous
ransplant were not at increased risk for developing
US, as smaller studies have suggested [7]. However,
he only patient with a nonmalignant disease to de-
elop HUS had received a second transplant for re-
urrent histiocytosis. In other series, TBI has been
hown to cause radiation nephritis, which is a distinct
ntity for HUS. In addition, we did not identify grade
or 4 organ toxicity as a risk factor for the develop- p
18ent of HUS. Cytokines such as interleukin 8 have
een implicated in vascular endothelial damage, lead-
ng to HUS [23]. Alternatively, immunosuppressants
uch as cyclosporine or tacrolimus are implicated [24].
n our series, all patients received a single calcineurin
nhibitor (cyclosporine) as GVHD prophylaxis, so in-
estigators were unable to study calcineurin use as a
isk factor.
Risk factors such as the use of ATG in the condi-
ioning regimen and CMV seronegativity of the re-
ipients suggest that an immunocompromised state
ay also play a role in the etiology of HUS. Recipient
MV seropositivity has been reported to be associated
ith a higher incidence of transplant-related mortality
n several studies [25-29]. Why CMV-seronegative
ecipients have a higher incidence of HUS is not clear,
ut this may be due to an undocumented viral infec-
ion. Clinical responses to administration of high-dose
ntravenous immunoglobulin support the hypothesis
hat immune dysregulation or infection is involved in
he pathogenesis of HUS [30]. Alternatively, recipient
MV seropositivity, ATG administration, or both
ay be surrogate markers for another identiﬁed risk
actor.
Some studies have shown that the reactivation of
MV or human herpesvirus 6 may be associated with
US [7,31-34], an observation suggesting that infec-
ious agents might be involved in the development of
US. We did not observe this in our series. In our
eries, grafts from unrelated donors and mismatched
amily members were depleted of T cells, a practice
hat decreased the rates of acute and chronic GVHD
ut is known to be associated with increased rates of
nfectious complications [35].
In addition, although we identiﬁed recipient CMV
eropositivity as a risk factor for the development of
US in our series, we did not identify CMV infection
r reactivation as a risk factor. This may be due to the
iagnostic and monitoring methods used when these
atients underwent transplantation. More sensitive as-
ays for CMVmay have been able to detect more cases
f CMV infection or reactivation.
Most of our patients who had HUS also had pro-
ound renal insufﬁciency. Most experienced signiﬁ-
ant deterioration in renal function and required an-
ihypertensive medications and EPO replacement.
owever, most did not require dialysis, and no survi-
or in our series required hemodialysis during HUS.
n most cases, renal function stabilized or improved
ith time after transplantation. The acute phase was
haracterized by profound hypertension that usually
equired therapy with multiple medications. Even
hough the primary cause of anemia in these patients
s the destruction of large numbers of red blood cells,
PO levels were also typically low as a result of the
enal insufﬁciency. Because of the small numbers of
atients, the authors were unable to compare the clin-
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Bcal courses of patients who received and who did not
eceive EPO. However, the EPO replacement is the-
retically beneﬁcial in this setting if measured EPO
evels are low, because it is given to treat patients with
enal insufﬁciency or failure. EPO has been shown to
ttenuate ischemia-induced injury in a variety of cell
ypes. Furthermore, EPO has enhanced functional
nd histologic recovery in animal models of both isch-
mic and nephrotoxin-induced acute renal failure.
PO is likely to exert its cytoprotective and mitogenic
ffects on endothelial and renal tubular cells. In our
atients, EPO may have provided a beneﬁcial effect
n renal functional recovery related to both endothe-
ial and tubule cell effects to reduce apoptosis and
timulate cell regeneration [36-38]. No treatment has
een proven curative [30,39]. No patient in our series
ied as a direct result of thrombotic microangiopathy.
ther series focusing on patients with TTP have
eported very high mortality rates (approaching 80%)
1-6]. The lower mortality rate in our series (6 of the
8 patients with HUS died) may be due to the lack of
NS involvement or the younger patient age.
An interesting observation in our study was the
endency for the calculated value for creatinine clear-
nce to exceed the measured GFR in patients with
osttransplantation HUS. Without careful serial mea-
urement of GFR, single DTPA and calculated creat-
nine clearances are of limited utility. We suggest that
trong consideration be given to obtaining DTPA
cans in these patients.
In conclusion, we found that HUS occurred in
pproximately 10% of children who had undergone
llogeneic BMT. The onset of HUS occurred a me-
ian of 6 months after transplantation, and most chil-
ren recovered with few sequelae; the natural history
f the disorder seems to be that of stable improvement
n renal function after the acute phase subsides. Patients
ho received ATG-containing conditioning regimens
nd were CMV seronegative were more likely to de-
elop this complication.
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